SYK Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 14.91%. Stryker Corp.'s return on equity of 14.06% beat Boston Scientific Corp.'s return on equity of 12.46%.

Stryker Corp. has a consensus price target of $428.96, signalling upside risk potential of 17.22%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 28.32%. Given that Boston Scientific Corp. has higher upside potential than Stryker Corp., analysts believe Boston Scientific Corp. is more attractive than Stryker Corp..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.92%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Stryker Corp.'s net income of $859M is higher than Boston Scientific Corp.'s net income of $755M. Notably, Stryker Corp.'s price-to-earnings ratio is 48.05x while Boston Scientific Corp.'s PE ratio is 52.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.80x versus 7.61x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 28.31%. Stryker Corp.'s return on equity of 14.06% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Stryker Corp. has a consensus price target of $428.96, signalling upside risk potential of 17.22%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $592.96 which suggests that it could grow by 4.08%. Given that Stryker Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Stryker Corp. is more attractive than Intuitive Surgical, Inc..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.92%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Stryker Corp.'s net income of $859M is higher than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Stryker Corp.'s price-to-earnings ratio is 48.05x while Intuitive Surgical, Inc.'s PE ratio is 75.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.80x versus 21.55x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 14.18% compared to Stryker Corp.'s net margin of 21.47%. Stryker Corp.'s return on equity of 14.06% beat Johnson & Johnson's return on equity of 33.27%.

Stryker Corp. has a consensus price target of $428.96, signalling upside risk potential of 17.22%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Stryker Corp. has higher upside potential than Johnson & Johnson, analysts believe Stryker Corp. is more attractive than Johnson & Johnson.

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.92%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Stryker Corp.'s net income of $859M is lower than Johnson & Johnson's net income of $5.2B. Notably, Stryker Corp.'s price-to-earnings ratio is 48.05x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.80x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 11.55%. Stryker Corp.'s return on equity of 14.06% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Stryker Corp. has a consensus price target of $428.96, signalling upside risk potential of 17.22%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.92 which suggests that it could grow by 10.54%. Given that Stryker Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Stryker Corp. is more attractive than Zimmer Biomet Holdings, Inc..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.92%. Zimmer Biomet Holdings, Inc. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.24 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Stryker Corp.'s net income of $859M is higher than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Stryker Corp.'s price-to-earnings ratio is 48.05x while Zimmer Biomet Holdings, Inc.'s PE ratio is 23.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.80x versus 2.31x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.